107 completed, 21 unknown, 15 terminated, 12 recruiting. 174 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 174 | Completed 107, Unknown 21, Terminated 15, Recruiting 12, Not yet recruiting 7, Withdrawn 6, Active not recruiting 4, Enrolling by invitation 1, Suspended 1 |
Follow Headache Disorders, Primary: new trials by email Literature Review of Headache Disorders, Primary trials Research Report on Headache Disorders, Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution, Placebo - Acute Mountain Sickness | Phase 4 | Not yet recruiting | Insel Gruppe AG, University Hospital Bern | 30 | 2027-06-01 | 2026-07-01 |
| Nortriptyline Compared With Amitriptyline for Migraine Prevention at SQUH Nortriptyline, Amitriptyline - Migraine | Phase 4 | Not yet recruiting | Sultan Qaboos University | 90 | 2027-05-01 | 2026-10-02 |
| Migraine Menopause Study Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution, Placebo Normal Saline (NS) - Migraine, Menopausal | Phase 4 | Not yet recruiting | Alberta Neurologic Centre | 120 | 2027-02-01 | 2026-11-04 |
| Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Migraine Atogepant 60 mg, Placebo - Migraine Disorders, Brain, Healthy Adult Participants | Phase 4 | Not yet recruiting | Konrad Peter Weber | 80 | 2027-01-01 | 2026-09-17 |
| A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India Rimegepant 75 mg ODT - Acute Treatment of Migraine | Phase 4 | Recruiting | Pfizer | 60 | 2026-07-24 | 2026-10-15 |
| Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM) Galcanezumab, Erenumab 70 mg, Eptinezumab - Migraine Associated Vertigo, Tinnitus | Phase 4 | Not yet recruiting | Stanford University | 120 | 2026-07-01 | 2026-06-17 |
| Treatment Patterns Among US Veterans Using Remote Electrical Neuromodulation (REN) for Migraine Treatment Nerivio REN device - Migraine, Acute Treatment of Migraine | Phase 4 | Completed | Theranica | 466 | 2026-01-09 | 2026-04-03 |
| Nerivio Efficacy Under High-Frequency Use Nerivio (REN device) - Migraine | Phase 4 | Active not recruiting | Theranica | 2000 | 2026-01-08 | 2026-01-13 |
| Treatment of Tension-type Headache by Zhixuan Analgesic Tablets Zhixuan Analgesic Tablet, Placebo - Frequent Episodic Tension-Type Headache | Phase 4 | Recruiting | Tongji Hospital | 212 | 2026-01-01 | 2026-10-14 |
| Evaluation of MIG-SPRAY Treatment on Migraine MIG-SPRAY - Migraine | Phase 4 | Active not recruiting | University Hospital, Clermont-Ferrand | 45 | 2025-09-15 | 2026-03-18 |
| Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US Rimegepant 75 MG - Migraine, Trigger Induced Migraine | Phase 4 | Recruiting | Medstar Health Research Institute | 60 | 2025-09-09 | 2025-12-24 |
| Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks Canvert-M (Produced by Alasht Pharmed co. Iran) - Migraine Disorders | Phase 4 | Recruiting | Alasht Pharmed | 30 | 2025-07-16 | 2025-07-30 |
| Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study Atogepant 60 mg, Propranolol 160 mg, Topiramate 100 mg - Migraine | Phase 4 | Recruiting | Mayo Clinic | 1335 | 2025-07-09 | 2026-10-19 |
| Acute Migraine Treatment in the ED With Gepants Rimegepant, Zavegepant - Migraine Headaches | Phase 4 | Terminated | Icahn School of Medicine at Mount Sinai | 9 | 2025-06-05 | 2026-04-29 |
| Management of Acute Tinnitus With Migraine Medications Nortriptyline, Topiramate, Paroxetine - Tinnitus | Phase 4 | Suspended | University of California, Irvine | 100 | 2025-06-01 | 2026-10-27 |
| Nerivio Efficacy by Time of Treatment Onset Nerivio - Migraine, Acute Treatment of Migraine | Phase 4 | Completed | Theranica | 55261 | 2025-05-07 | 2025-07-31 |
| A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications Eptinezumab - Migraine | Phase 4 | Completed | H. Lundbeck A/S | 164 | 2024-12-18 | 2026-09-09 |
| Comparison of the Effectiveness of First-line Preventive Treatment of Migraine in Primary Care Topiramate, Flunarizine, Amitriptyline - Migraine | Phase 4 | Not yet recruiting | Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina | 460 | 2024-10-01 | 2024-07-12 |
| A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache Rimegepant, Rizatriptan Benzoate - Migraine | Phase 4 | Recruiting | Antonios Likourezos | 80 | 2024-09-01 | 2026-09-24 |
| Impact of Combined Oral Contraceptive Pills on Migraine Combined oral contraceptive, Vaginal Ring - Migraine | Phase 4 | Recruiting | Kafrelsheikh University | 400 | 2024-07-15 | 2024-10-09 |
Showing 20 of 174. Sign in to see all of them.
Migraine Disorders (159) · Headache (33) · Migraine with Aura (10) · Migraine without Aura (10) · Emergencies (8) · Cluster Headache (6) · Pain (4) · Tension-Type Headache (4) · Headache Disorders (3) · Recurrence (3) · Tinnitus (3) · Epilepsy (2) · Headache Disorders, Secondary (2) · Agnosia (1) · Altitude Sickness (1)
Central Nervous System Diseases (174) · Nervous System Diseases (174) · Brain Diseases (173) · Headache Disorders (171) · Pathological Conditions, Signs and Symptoms (51) · Neurologic Manifestations (44) · Signs and Symptoms (44) · Pain (32) · Pathologic Processes (13) · Disease Attributes (11) · Otorhinolaryngologic Diseases (7) · Ear Diseases (6) · Migraine Disorders (6) · Trigeminal Autonomic Cephalalgias (6)
erenumab (20) · Topiramate (17) · Sumatriptan (13) · Metoclopramide (11) · rimegepant sulfate (10) · Botulinum Toxins, Type A (8) · Saline Solution (8) · Bupivacaine (7) · Naproxen (7) · Ibuprofen (6) · Propranolol (6) · Sodium Chloride (6) · sumatriptan-naproxen (6) · Acetaminophen (5) · Amitriptyline (5)
Montefiore Medical Center (10) · Amgen (6) · Cady, Roger, M.D. (5) · Pfizer (5) · Danish Headache Center (4) · Mayo Clinic (4) · Thomas Jefferson University (4) · Allergan (3) · Clinvest (3) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta (3) · H. Lundbeck A/S (3) · Novartis Pharmaceuticals (3) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (3) · Theranica (3) · University of California, Irvine (3)
United States (98) · Italy (14) · France (11) · Denmark (9) · Germany (9) · Spain (9) · Turkey (Türkiye) (9) · Poland (8) · United Kingdom (8) · Canada (7) · Australia (6) · China (6) · Finland (6) · Austria (5) · Czechia (4)
Roger K Cady, MD (8) · Alit Stark-Inbar, PhD (3) · Benjamin W Friedman, MD, MS (3) · Messoud Ashina, MD (3) · Dawn Marcus, MD (2) · Messoud Ashina, Prof. (2) · Ortho McNeil Neurologics, Inc. Clinical Trial (2) · William B Young, MD (2) · Abeer Salamah, ass prof (1)
PMID 37303034, PMID 11914403, PMID 12807523, PMID 23567060, PMID 40275185, PMID 8984084, PMID 11535479, PMID 12598264, PMID 12764341, PMID 14633551, PMID 15107371, PMID 15985582, PMID 16324164, PMID 16492233, PMID 17105455, PMID 17157685, PMID 17300358, PMID 17445101, PMID 17501849, PMID 17504651, PMID 17955107, PMID 18006188, PMID 18156535, PMID 18384420, PMID 18387702, PMID 18534808, PMID 18549410, PMID 18958996, PMID 19486178, PMID 19817885, PMID 20045576, PMID 20236340, PMID 20396496, PMID 20880898, PMID 20974598, PMID 21592098, PMID 21812775, PMID 21880111, PMID 21942531, PMID 22460943, PMID 23936605, PMID 24020994, PMID 24030685, PMID 24127709, PMID 24180163, PMID 25323219, PMID 25338927, PMID 25366551, PMID 25415168, PMID 25505035
2019 (5), 2018 (3), 2017 (1), R01DK100368 (1), UL1TR000135 (1)